{"title":"新产品条目[阿米万塔单抗vmjw、阿尼福鲁单抗fnia(同类第一)、ascimib、阿托格潘、阿伐葡糖苷酶alfa ngpt、比美基珠单抗、克拉斯科酮、多纳非尼、洛那培生长激素tcgd、莫博替尼、氨基多芬/奥氮平(新组合)","authors":"","doi":"10.1358/dot.2021.57.12.3388997","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New product intros [amivantamab-vmjw, anifrolumab-fnia (first-in-class), asciminib, atogepant, avalglucosidase alfa-ngpt, bimekizumab, clascoterone, donafenib, lonapegsomatropin-tcgd, mobocertinib, samidorphan/olanzapine (new combination), teserpaturev, tisotumab vedotin (first-in-class), vosoritide\",\"authors\":\"\",\"doi\":\"10.1358/dot.2021.57.12.3388997\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":85144,\"journal\":{\"name\":\"Medicamentos de actualidad. Drugs of today\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicamentos de actualidad. Drugs of today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2021.57.12.3388997\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2021.57.12.3388997","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
New product intros [amivantamab-vmjw, anifrolumab-fnia (first-in-class), asciminib, atogepant, avalglucosidase alfa-ngpt, bimekizumab, clascoterone, donafenib, lonapegsomatropin-tcgd, mobocertinib, samidorphan/olanzapine (new combination), teserpaturev, tisotumab vedotin (first-in-class), vosoritide